Joseph K. Belanoff's Stock Transactions in Corcept Therapeutics Inc.

Joseph K. Belanoff, Chief Executive Officer and Director of Corcept Therapeutics Inc., reported multiple sales of the company's common stock on August 1, 2025. The transactions were executed under a Rule 10b5-1 trading plan adopted on November 26, 2024. Belanoff sold a total of 40,000 shares at weighted average prices ranging from $67.8063 to $69.6483 per share. The shares were held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust, over which Belanoff has voting power but disclaims beneficial ownership except for his pecuniary interest. Following these transactions, Belanoff's total holdings in Corcept Therapeutics Inc. decreased to 2,861,370 shares.